Arrowhead Pharmaceuticals (ARWR) Stock Rating Reaffirmed by William Blair

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “outperform” rating reiterated by stock analysts at William Blair in a report released on Wednesday.

ARWR has been the topic of a number of other reports. BidaskClub lowered Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 16th. Chardan Capital reaffirmed a “buy” rating and set a $17.50 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 13th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $17.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, June 29th. B. Riley boosted their target price on Arrowhead Pharmaceuticals from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 8th. Finally, Cantor Fitzgerald set a $18.00 target price on Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, September 6th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $21.45.

Shares of ARWR traded up $0.16 during midday trading on Wednesday, reaching $13.51. The stock had a trading volume of 18,140 shares, compared to its average volume of 3,236,698. Arrowhead Pharmaceuticals has a 52 week low of $3.01 and a 52 week high of $22.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.69 and a current ratio of 8.69. The company has a market capitalization of $1.19 billion, a PE ratio of -29.06 and a beta of 1.75.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.62 million. On average, equities research analysts forecast that Arrowhead Pharmaceuticals will post -0.65 EPS for the current fiscal year.

In related news, CEO Christopher Richard Anzalone sold 100,000 shares of the company’s stock in a transaction on Friday, August 31st. The stock was sold at an average price of $14.45, for a total transaction of $1,445,000.00. Following the transaction, the chief executive officer now directly owns 1,868,789 shares of the company’s stock, valued at $27,004,001.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kenneth Allen Myszkowski sold 45,000 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $19.34, for a total value of $870,300.00. Following the transaction, the chief financial officer now directly owns 335,815 shares in the company, valued at $6,494,662.10. The disclosure for this sale can be found here. Insiders have sold 309,834 shares of company stock worth $4,697,151 over the last three months. 4.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. RTW Investments LP grew its stake in Arrowhead Pharmaceuticals by 184.6% in the second quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock valued at $112,874,000 after purchasing an additional 5,382,981 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 108.1% during the 2nd quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock worth $96,342,000 after acquiring an additional 3,679,986 shares in the last quarter. First Manhattan Co. boosted its stake in shares of Arrowhead Pharmaceuticals by 11.6% during the 3rd quarter. First Manhattan Co. now owns 5,053,925 shares of the biotechnology company’s stock worth $96,883,000 after acquiring an additional 523,675 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Arrowhead Pharmaceuticals by 380.1% during the 2nd quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock worth $14,464,000 after acquiring an additional 841,982 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 67.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 457,891 shares of the biotechnology company’s stock worth $6,228,000 after acquiring an additional 184,849 shares in the last quarter. Hedge funds and other institutional investors own 58.77% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Further Reading: What is the NASDAQ?

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply